Global Biopharmaceutical and Bio-CDMO Market Growth (Status and Outlook) 2024-2030

Global Biopharmaceutical and Bio-CDMO Market Growth (Status and Outlook) 2024-2030

The global Biopharmaceutical and Bio-CDMO market size is projected to grow from US$ 28120 million in 2024 to US$ 60540 million in 2030; it is expected to grow at a CAGR of 13.6% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Biopharmaceutical and Bio-CDMO Industry Forecast” looks at past sales and reviews total world Biopharmaceutical and Bio-CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Biopharmaceutical and Bio-CDMO sales for 2023 through 2029. With Biopharmaceutical and Bio-CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Biopharmaceutical and Bio-CDMO industry.

This Insight Report provides a comprehensive analysis of the global Biopharmaceutical and Bio-CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Biopharmaceutical and Bio-CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Biopharmaceutical and Bio-CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biopharmaceutical and Bio-CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biopharmaceutical and Bio-CDMO.

United States market for Biopharmaceutical and Bio-CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Biopharmaceutical and Bio-CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Biopharmaceutical and Bio-CDMO is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Biopharmaceutical and Bio-CDMO players cover Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Biopharmaceutical and Bio-CDMO market by product type, application, key players and key regions and countries.

Segmentation by Type:
Cell and Gene Therapies
Antibodies
Vaccines
Other

Segmentation by Application:
SMBs
Large Companies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Cell and Gene Therapies
Antibodies
Vaccines
Other

Segmentation by Application:
SMBs
Large Companies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza
Catalent
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim
WuXi AppTech
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.